Work

A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps9631

Authors: Chee Khoon Lee, Shalini Subramaniam, Antony Mersiades, Jenna Mitchell, Hannora Jurkovic, Mariya Walker, Loc Le, Chris Brown, Benjamin J. Solomon, Tom John, Martin R. Stockler, Bin-Chi Liao, James Chih-Hsin Yang, Chao-Hua Chiu

Institutions: St George Hospital, The University of Sydney, Peter MacCallum Cancer Centre, National Taiwan University Hospital, Taipei Veterans General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031232929

Cites:

Cited by: 4

Related to: 10